Last updated on February 2020

First-in-human study of ATR inhibitor BAY1895344 in patients with advanced solid tumors and lymphomas


Brief description of study

The purpose of the proposed trial is to evaluate the safety and tolerability of BAY1895344, and to identify the maximum tolerated dose of BAY1895344 that could be safely given to cancer patients.  Further, the response of the cancer to the treatment will be determined.

 

Clinical Study Identifier: TX236275

Find a site near you

Start Over

Fairfax-Northern Virginia Hematology/Oncology, PC

Located in: Fairfax, Virginia United States
  Connect »

Weill Cornell Medical College

Located in: New York, New York United States
  Connect »

Emory University

Located in: Atlanta, Georgia United States
  Connect »

University of Utah

Located in: Salt Lake City, Utah United States
  Connect »

Gabrail Cancer Center

Located in: Canton, Ohio United States
  Connect »

University Hospitals Cleveland Medical Center

Located in: Cleveland, Ohio United States
  Connect »

H. Lee Moffitt Cancer Center & Research Institute

Located in: Tampa, Florida United States
  Connect »

Jefferson Medical College

Located in: Philadelphia, Pennsylvania United States
  Connect »

Dana-Farber Cancer Institute

Located in: Boston, Massachusetts United States
  Connect »

Texas Oncology- San Antonio Northeast

Located in: San Antonio, Texas United States
  Connect »

Massachusetts General Hospital

Located in: Boston, Massachusetts United States
  Connect »

US Oncology

Located in: Eugene, Oregon United States
  Connect »

US Oncology

Located in: Fort Worth, Texas United States
  Connect »